arabinofuranosyluracil has been researched along with Lymphoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coderre, JA; Fox, JJ; Matsuda, A; Santi, DV; Watanabe, KA | 1 |
| Müller, WE; Zahn, RK | 1 |
| Akerman, S; Chan, K; Dantis, E; DeAngelis, LM; Kreis, W | 1 |
3 other study(ies) available for arabinofuranosyluracil and Lymphoma
| Article | Year |
|---|---|
Mechanism of action of 2',5-difluoro-1-arabinosyluracil.
Topics: Animals; Arabinofuranosyluracil; Arabinonucleotides; Cell Line; Cell Survival; Chromatography, Gel; Deoxyuracil Nucleotides; Fluorodeoxyuridylate; Lymphoma; Mice; Spectrophotometry, Ultraviolet; Thymidylate Synthase; Uridine | 1983 |
Metabolism of 1-beta-D-arabinofuranosyluracil in mouse L5178Y cells.
Topics: Animals; Arabinofuranosyluracil; Arabinonucleosides; Cell Division; Cells, Cultured; DNA, Neoplasm; Lymphoma; Mice; Neoplasms, Experimental; Nucleic Acid Synthesis Inhibitors; Phosphorylation; Uridine | 1979 |
Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside.
Topics: Arabinofuranosyluracil; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Female; Half-Life; Humans; Lymphoma; Male; Metabolic Clearance Rate; Middle Aged | 1992 |